Milrinone is a miscellaneous inotropic drug used in the short-term management of heart failure. The only way this drug is approved to be administered is intravenously.
At the Sterling Winthrop Research Institute, Milrinone was first created in the 1980s. Prior to being discontinued, Sanofi-Aventis US marketed it under the trade name PRIMACOR® after the FDA gave its approval on December 31, 1987.
Patients with acute decompensated heart failure are recommended to be treated with milrinone for no more than 48 hours.
Milrinone should be administered while being closely monitored with the necessary electrocardiographic tools in a setting that is prepared to address possible cardiac events right away, including ventricular arrhythmias.
To learn more about inotropic drug here
brainly.com/question/14326069
#SPJ4
